Work

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

Year: 2012

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2012-3853

Authors: Heather Huet, Alwin Schuller, Jing Li, Jennifer Johnson, Bruno Dombrecht, Kris Meerschaert, Karen Cromie, Sanela Bilic, Sharon Li, Andrew Garner, Sandra Nunes, Rajiv Chopra, Kirk Clark, Megan Yao, Stephen Fawell, David Stover, William R. Sellers, Seth Ettenberg

Institutions: Ablynx (Belgium), Novartis (United States)

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2058776690

Cites:

Cited by: 7

Related to: 10